[Anti-thrombosis effect and its mechanism of Qingkailing injection].
OBJECTIVE
To investigate the anti-thrombosis effect and its mechanism of Qingkailing injection (QKL).


METHODS
SD rats were randomly divided into control group, model group and QKL 2.5, 5.0, 10 groups. QKL were given (i.p.) to rats once a day for successively 4 days. The rats in all groups but control were pretreated with carrageenin (Ca) i.p. at 16 h before the last dose of QKL and followed by intravenous injection of endotoxin ( LPS fom E. coli O111:B4) 50 microg x kg(-1) 30 min after the last dosing of QKL. Thrombosis in rat tails were observed at 24 h after injection of LPS. The number of white blood cells and platelets, serum TNF-alpha, IL-6 level, CD11b/CD18 expression of white blood cells and platelet aggregation were analysed.


RESULTS
QKL obviously inhibited the LPS/Ca-induced thrombosis as showed a reduced infarction range due to thrombosis in tails. The sera concentration of TNF-alpha and IL-6, expression of CD11b/CD18 in WBC and platelet coagulation rate were reduced after QKL treatment.


CONCLUSIONS
The anti-thrombosis action of QKL is associated with inhibition of WBC activation and adherence, reduction of inflammatory factor release and abating of platelet coagulation rate. The anti-thrombosis mechanism of QKL is consistent with its function of clearing away heat-evil and toxic materials.
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Chunyu
C
Cao
Aihua
A
Liang
Yong
Y
Zhao
Ting
T
Liu
Chunying
C
Li
Yan
Y
Yi
Jinhua
J
Wang
Baoyun
B
Xue
Timothy M
TM
Chan
D000818:Animals; D018845:CD11 Antigens / Q000235:genetics / Q000378:metabolism; D018821:CD18 Antigens / Q000235:genetics / Q000378:metabolism; D004195:Disease Models, Animal; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage*; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D007274:Injections, Intraperitoneal; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013927:Thrombosis / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
D018845:CD11 Antigens; D018821:CD18 Antigens; D004365:Drugs, Chinese Herbal; D005343:Fibrinolytic Agents; D015850:Interleukin-6; C504928:Qingkailing; D014409:Tumor Necrosis Factor-alpha